The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
EFFEKTOR is a vanguard, multicenter, phase 2 randomized, double blinded, placebo controlled
clinical trial to determine the feasibility, tolerability, safety, and efficacy of finerenone
in kidney transplant recipients (KTRs). One hundred fifty (150) KTRs will be randomized in a
2:1 ratio of finerenone to placebo, with two embedded substudies: (i) a kidney biopsy
substudy in 50 participants who undergo a research kidney biopsy prior to randomization and
at the end of active treatment; and (ii) a functional MRI (fMRI) substudy in 50 participants
who undergo fMRI prior to randomization and at the end of active treatment.